| Literature DB >> 23306583 |
Constance Schultsz1, Martinus C J Bootsma, Huynh T Loan, Tran T T Nga, Le T P Thao, Tran T D Thuy, James Campbell, Le M Vien, Ngo T Hoa, Nguyen V M Hoang, Ferdinand Wit, Nguyen V V Chau, Jeremy Farrar, Marc J M Bonten, Lam M Yen.
Abstract
PURPOSE: To quantify the effects of barrier precautions and antibiotic mixing on prevalence and acquisition of five drug-resistant microorganisms within a single tetanus intensive care unit at a tertiary referral hospital in Ho Chi Minh City, Vietnam.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23306583 PMCID: PMC3607730 DOI: 10.1007/s00134-012-2771-1
Source DB: PubMed Journal: Intensive Care Med ISSN: 0342-4642 Impact factor: 17.440
Infection control measures implemented at the start of study year 2
| Target | Infection control measures |
|---|---|
| Exogenous acquisition of microorganisms | Reinforcement of hand hygiene Limit exchange of equipment, materials, and staff between patients by allocating dedicated materials to individual patients at bedside Revise washing procedures: allocate wash bowls to individual patients Measure compliance by direct observations |
| Exogenous acquisition of MRSA | Reporting of results of surveillance cultures Sign indicating positivity at the bedside |
| Endogenous acquisition of ESBL-positive | Change in empirical antimicrobial therapy resulting in three regimens applied simultaneously (“antibiotic mixing”) |
Measures were targeted at reducing colonization by exogenous or endogenous acquisition. The target of each (set of) measure(s) is indicated
Patient characteristics on admission and during intensive care stay, in year 1 (baseline) and year 2 (infection control measures implemented) of study (includes only patients with admission and discharge within total study period)
| Characteristica | Year 1 | Year 2 |
|
|---|---|---|---|
| Age, years (excluding neonates) | |||
| No. of patientsc | 167 | 150 | |
| Median | 38 | 42 | 0.23 |
| Range | 5–88 | 2–84 | |
| Neonates no. | 5 (2.9) | 5 (3.1) | |
| Male sex—no./total no. (%)c | 124/174 (71.3) | 120/157 (76.4) | |
| Admission from other hospital—no./total no. (%) | 149/174 (85.6) | 137/157 (87.3) | 0.67 |
| >48 h in other hospital—no./total no. (%)c | 27/144 (18.8) | 26/128 (20.3) | |
| Tetanus Severity Scored | |||
| No. of patientsc | 166 | 151 | |
| Median | 0.0 | 0.0 | 0.007 |
| Range | −6 to 17 | −6 to 20 | |
| Duration of stay (days) | |||
| No. of patients | 174 | 161 | |
| Median | 12 | 17 | 0.004 |
| Range | 1–66 | 1–148 | |
| No. of patient days | 2,527 | 3,235 | |
| Patients with tracheostomy—no./total no. (%) | 83/174 (47.7) | 97/159 (61.0) | 0.015 |
| Total no. of tracheostomy days | 1,651 | 2,350 | |
| No. of patients | 83 | 97 | |
| Median | 20 | 21 | 0.25 |
| Range | 1–57 | 1–145 | |
| Patients ventilated—no./total no. (%) | 71/174 (40.8) | 97/159 (61.0) | 0.0002 |
| Total no. of ventilation days | 1,089 | 1,713 | |
| No. of patientsc | 70 | 96 | |
| Median | 16 | 18 | 0.36 |
| Range | 1–41 | 1–88 | |
| No. nosocomial pneumonia/1,000 ventilation days at risk | 56 | 40 | 0.17 |
| Patients with urinary catheter—no./total no. (%)c | 100/165 (60.6) | 109/159 (68.6) | 0.14 |
| Total no. of catheter days | 1,419 | 1,859 | |
| No. of patientsc | 94 | 108 | |
| Median | 13.5 | 14.5 | 0.54 |
| Range | 2–63 | 2–85 | |
| No. urinary tract infection/1,000 catheter days at risk | 12.8 | 15.1 | 0.61 |
aClinical files were missing for two patients in year 2
bDetermined using χ 2 test or Wilcoxon-rank test
cNumber of patients for whom data were available
dThe Tetanus Severity Score is a composite score calculated from the total of individual scores of age, time from first symptom to admission, difficulty breathing on admission, co-existing medical conditions, entry site, highest blood pressure recorded during first day in hospital, highest heart rate recorded during first day in hospital, lowest heart rate recorded during first day in hospital, and highest temperature recorded during first day in hospital. The score ranges between −8 and 48 and a score ≥8 is predictive of death. It is not applicable to neonates [10]
Antibiotic usage in study years 1 and 2
| Agent | Defined daily dosages | Rate | 95 % CI | |
|---|---|---|---|---|
| Year 1 | Year 2 | |||
| Ceftazidime | 173 | 81 | 0.47 | 0.40–0.55 |
All 3rd-generation cephalosporines | 179 | 85 | 0.48 | 0.41–0.55 |
| Ciprofloxacine | 13 | 59 | 4.46 | 3.10–6.59 |
| All fluoroquinolones | 81 | 99 | 1.22 | 1.02–1.46 |
| Piperacillin–tazobactam | 8 | 59 | 7.2 | 4.63–11.76 |
| Amikacin | 207 | 205 | 0.99 | 0.88–1.11 |
| Imipenem | 80 | 48 | 0.60 | 0.48–0.74 |
| Penicillin | 261 | 167 | 0.64 | 0.57–0.71 |
| Metronidazole | 165 | 217 | 1.31 | 1.17–1.48 |
Fig. 1Estimated prevalence of Pseudomonas aeruginosa (a), gentamicin-resistant Klebsiella pneumoniae (b), amikacin-resistant Acinetobacter spp. (c), methicillin-resistant Staphylococcus aureus (d), extended spectrum beta-lactamase-producing Enterobacteriaceae (excl. K. pneumoniae) (e) on tetanus intensive care unit during year 1 (May 2004–April 2005) and year 2 (May 2005–April 2006). Red indicates the number of patients colonized at a given time point, green the number of patients uncolonized, and blue the number of patients with unknown colonization status, i.e., patient days between the last negative culture result and the first positive culture result, or patient days between the last negative result and discharge
Number of patients colonized (includes only patients with admission in study period) and maximum likelihood estimators for the acquisition parameters α (endogenous acquisition) and β (exogenous acquisition) and related quantities, for all pathogens under study (using data obtained from all patients present on ward during study period), in year 1 and year 2
| Year 1 | Year 2 |
| |
|---|---|---|---|
Methicillin-resistant
| |||
| Patients with a positive culture—no./total no. (%) | 44/174 (25.3) | 19/161 (11.8) | |
| Patients with a positive culture on admission—no./total no. (%) | 5/174 (2.9) | 4/161 (2.5) | 0.83 |
| Acquisition parameter | 0.005 (0.002; 0.012) | 0.005 (0.002; 0.009) | |
| Acquisition parameter | 0.117 (0.079; 0.162) | 0.015 (0.0; 0.055) | |
| Estimated daily prevalence—% (95 % CI) | 34.0 (33.9; 34.2) | 10.3 (10.26; 10.31) | |
| Acquisitions—estimated no. (95 % CI) | 53.7 (51.8; 55.8) | 18.8 (18.1; 19.8) | |
| Exogenous acquisitions—estimated % of total no. of acquisitions (95 % CI) | 83.7 (69.1; 90.9) | 21.7 (0; 55.5) | |
| ESBL-positive | |||
| Patients with a positive culture–no./total no. (%) | 94/174 (54.0) | 90/161 (55.9) | |
| Patients with a positive culture on admission—no./total no. (%) | 22/174 (12.6) | 10/161 (6.2) | 0.04 |
| Acquisition parameter | 0.086 (0.043; 0.107) | 0.020 (0; 0.059) | |
| Acquisition parameter | 0 (0.0; 0.085) | 0.105 (0.024; 0.0173) | |
| Estimated daily prevalence—% (95 % CI) | 61.3 (61.1; 61.5) | 55.0 (54.9; 55.0) | |
| Acquisitions—estimated no. (95 % CI) | 86.5 (84.4; 88.7) | 100.2 (98.8; 101.8) | |
| Exogenous acquisitions—estimated % of total no. of acquisitions (95 % CI) | 0 (0; 48.2) | 70.8 (17.0; 100.0) | |
|
| |||
| Patients with a positive culture—no./total no. (%) | 66/174 (37.9) | 95/161 (59) | |
| Patients with a positive culture on admission—no./total no. (%) | 7/174 (4.0) | 9/161 (5.6) | 0.5 |
| Acquisition parameter | 0.042 (0.01; 0.073) | 0.085 (0.026; 0.119) | |
| Acquisition parameter | 0.037 (0; 0.114) | 0.026 (0; 0.132) | |
| Estimated daily prevalence—% (95 % CI) | 53.4 (53.2; 53.7) | 66.4 (66.3; 66.5) | |
| Acquisitions—estimated no. (95 % CI) | 71.3 (68.8; 74.1) | 107.6 (105.8; 109.6) | |
| Exogenous acquisitions—estimated % of total no. of acquisitions (95 % CI) | 28.8 (0; 81.5) | 15.1 (0; 74.0) | |
Gentamicin-resistant
| |||
| Patients with a positive culture—no./total no. (%) | 86/174 (49.4) | 92/161 (57.1) | |
| Patients with a positive culture on admission—no./total no. (%) | 19/174 (10.9) | 15/161 (9.3) | 0.63 |
| Acquisition parameter | 0.102 (0.049; 0.119) | 0.075 (0.031; 0.091) | |
| Acquisition parameter | 0 (0; 0.094) | 0 (0; 0.087) | |
| Estimated daily prevalence—% (95 % CI) | 65.7 (65.4; 65.9) | 58.4 (58.4; 58.5) | |
| Acquisitions—estimated no. (95 % CI) | 90.3 (87.7; 93.1) | 100.9 (99.6; 102.5) | |
| Exogenous acquisitions—estimated % of total no. of acquisitions (95 % CI) | 0 (0; 49.8) | 0 (0; 57.7) | |
| Amikacin-resistant | |||
| Patients with a positive culture—no./total no. (%) | 85/174 (48.9) | 89/161 (55.3) | |
| Patients with a positive culture on admission—no./total no. (%) | 21/174 (12.1) | 7/161 (4.3) | 0.01 |
| Acquisition parameter | 0.047 (0.014; 0.090) | 0.066 (0.005; 0.096) | |
| Acquisition parameter | 0.067 (0; 0.147) | 0.025 (0; 0.143) | |
| Estimated daily prevalence—% (95 % CI) | 57.1 (56.9.7; 57.2) | 60.2 (60.1; 60.3) | |
| Acquisitions—estimated no. (95 % CI) | 86.9 (84.8; 89.4) | 102.5 (100.8; 104.3) | |
| Exogenous acquisitions—estimated % of total no. of acquisitions (95% CI) | 39.8 (0; 80.4) | 17.0 (0; 93.6) | |
MLE maximum likelihood estimate
aDetermined using χ 2 test for independent observations only
Fig. 2Contour plots of the likelihood of the acquisition parameters α (endogenous acquisition, horizontal axis) and β (exogenous acquisition, vertical axis) for Pseudomonas aeruginosa, gentamicin-resistant Klebsiella pneumoniae, amikacin-resistant Acinetobacter spp., methicillin-resistant Staphylococcus aureus (MRSA), extended spectrum beta-lactamase-producing Enterobacteriaceae (excl. K. pneumoniae) (ESBL-producing Enterobacteriaceae) in year 1 and year 2. The black dot represents the maximum likelihood estimate (MLE), the shaded area represents the corresponding 95 % confidence interval (CI). The line represents the parameters for which the endogenous route and the exogenous route are equally important. For example, the MLE of exogenous acquisition parameter β of MRSA was 0.117 (95 % CI 0.079; 0.162) in year 1 and 0.015 (0.0; 0.055) in year 2, indicating that the probability of exogenous acquisition of MRSA per unit of time for a given prevalence of MRSA on the ward was 8 (0.117/0.015) times lower in year 2 compared to year 1. In contrast, the MLEs of endogenous acquisition parameter α were both 0.005 (95 % CI 0.002; 0.012 and 0.002; 0.009) in year 1 and year 2, indicating that the daily probability of endogenous acquisition of MRSA remained 0.5 % throughout the entire study period
Fig. 3Pulse field gel electrophoreses analysis of all first methicillin-resistant Staphylococcus aureus (MRSA) strains, isolated from patients admitted to the tetanus ICU during the entire study period (May 2004–April 2006). Band patterns were generated by restriction enzyme digestion of total bacterial DNA. Each row depicts the band pattern of a single isolate and the date of sample collection (first column), date of admission (second column), and date of discharge (third column) of the patient the isolate was cultured from. Identical band patterns indicate clonality as can be expected after exogenous transmission of MRSA